GlassScriptPhysician profile
Sarah L Matcha
NPI 1891944013
$16,636.91
in general payments reported to CMS, 2019-2025
24 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15K · 2022: $239 · 2023: $912 · 2024: $418 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837 · Consulting Fee: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.46 |
| Consulting Fee | $700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $8,733.65 | 2021-2023 | Ingrezza, Ongentys |
| Acorda Therapeutics, INC | $6,693.37 | 2021-2023 | Inbrija, Ampyra |
| Amneal Pharmaceuticals LLC | $192.49 | 2021-2025 | Rytary, Crexont |
| Acadia Pharmaceuticals INC | $157.73 | 2021-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $137.72 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbott Laboratories | $112.63 | 2022-2025 | Infinity |
| Tg Therapeutics, INC. | $77.45 | 2023-2025 | |
| Boston Scientific Corporation | $58.65 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $56.24 | 2021 | |
| Genzyme Corporation | $51.46 | 2024-2025 | |
| Abbvie INC. | $48.91 | 2021-2024 | |
| Eisai INC. | $47.47 | 2024 | |
| Lilly USA, LLC | $35.56 | 2024-2025 | Reyvow, Emgality, Kisunla |
| Biogen, INC. | $29.33 | 2021 | |
| Adamas Pharmaceuticals, INC. | $28.80 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $28.02 | 2024 | |
| Microtransponder, INC. | $26.32 | 2024 | |
| Mirum Pharmaceuticals, INC. | $24.25 | 2025 | Cholbam |
| Genentech USA, INC. | $24.13 | 2024 | Ocrevus |
| Merz Pharmaceuticals, LLC | $16.61 | 2025 | Inbrija, Ampyra, Xeomin |
| Kyowa Kirin, INC. | $16.03 | 2022 | |
| Sunovion Pharmaceuticals INC. | $13.70 | 2021 | |
| Pfizer INC. | $13.40 | 2024 | |
| Medtronic, INC. | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Matcha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.